<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746405</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00101172</org_study_id>
    <nct_id>NCT03746405</nct_id>
  </id_info>
  <brief_title>Effects of Connectivity-based rTMS and State-Dependency on Amygdala Activation</brief_title>
  <acronym>ConnecTMS</acronym>
  <official_title>Effects of Connectivity-based rTMS and State-Dependency on Amygdala Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a highly debilitating disease with response rates to&#xD;
      pharmacological treatment rarely exceeding 60%. Preliminary attempts have been made to use&#xD;
      repetitive transcranial magnetic stimulation (rTMS) as a non-pharmacological treatment&#xD;
      alternative, but thus far rTMS approaches have demonstrated only modest efficacy. A major&#xD;
      factor contributing to these limited effects stems from the depth penetration of TMS, which&#xD;
      is not sufficient to directly modulate deep subcortical structures, such as the amygdala,&#xD;
      that are affected in PTSD. Moreover, while rTMS effects have been shown to be&#xD;
      state-dependent, (i.e. vary substantially according to the neural state during stimulation),&#xD;
      this important factor is rarely considered during the clinical application of rTMS. The&#xD;
      current study addresses both of these limitations to improve the therapeutic efficacy of rTMS&#xD;
      for PTSD. Here we will develop a protocol to test if connectivity-based rTMS is able to&#xD;
      modulate amygdala activity through the functional connections with medial prefrontal cortex,&#xD;
      taking advantage of state-dependency to enhance rTMS effects by actively engaging the&#xD;
      amygdala through a fear perception task. BOLD activation in the amygdala and its connectivity&#xD;
      with the frontal cortex will constitute the primary outcomes to test rTMS efficacy. Heart&#xD;
      rate variability and skin galvanic responses, acquired during the presentation of fearful&#xD;
      faces, will be used as continuous moderators of task engagement during rTMS. If successful,&#xD;
      this study will pave the way for a large-scale study to investigate whether state-dependent,&#xD;
      connectivity-based rTMS of the amygdala can improve rTMS efficacy as a clinical treatment for&#xD;
      PTSD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2019</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Effect of a rTMS Session on Brain Activation as Measured by the Cerebral Blood Flow (Blood Oxygenation Level Dependent Signal)</measure>
    <time_frame>right after the rTMS session, up to one hour</time_frame>
    <description>Blood oxygenation level dependent (BOLD) will be assessed to evaluate the acute effect of rTMS applied over the medial prefrontal cortex on the amygdala activation.&#xD;
This outcome (expressed a z-score) represents the amygdala activation, either after active rTMS or after sham rTMS.&#xD;
Higher z-scores for active than for sham rTMS indicates that amygdala activity increases after active rTMS compared to sham rTMS, on the other hand lower z-score after active rTMS vs. after Sham rTMS indicated that the amygdala activity would have been reduced with active rTMS.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Amygdala Activation</condition>
  <arm_group>
    <arm_group_label>Repetitive TMS (rTMS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham repetitive TMS (rTMS)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive transcranial magnetic stimulation</intervention_name>
    <description>excitatory 5Hz rTMS will be used</description>
    <arm_group_label>Repetitive TMS (rTMS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham repetitive transcranial magnetic stimulation</intervention_name>
    <description>an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
    <arm_group_label>Sham repetitive TMS (rTMS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age Restrictions: Young Group (from 18 to 35 years old)&#xD;
&#xD;
          -  Use of effective method of birth control for women of childbearing capacity.&#xD;
&#xD;
          -  Willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent (within the past 6 months) history of substance abuse or dependence.&#xD;
&#xD;
          -  Current serious medical illness.&#xD;
&#xD;
          -  History of seizure, epilepsy, stroke, brain surgery, head injury, cranial metal&#xD;
             implants, known structural brain lesion, devices that may be affected by rTMS or MRI&#xD;
             (pacemaker, medication pump, cochlear implant, implanted brain stimulator)&#xD;
&#xD;
          -  Inability or unwilling to give informed consent.&#xD;
&#xD;
          -  Diagnosed any Axis I DSM-IV disorder (MINI, DSM-IV).&#xD;
&#xD;
          -  Clinically defined neurological disorder.&#xD;
&#xD;
          -  Increased risk of seizure for any reason, including prior diagnosis of increased&#xD;
             intracranial pressure, or currently taking medication that lowers the seizure&#xD;
             threshold.&#xD;
&#xD;
          -  Claustrophobia (MRI scanner).&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lysianne Beynel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <results_first_submitted>October 9, 2020</results_first_submitted>
  <results_first_submitted_qc>October 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2020</results_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03746405/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03746405/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03746405/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Across the 25 enrolled participants, 7 were excluded after the first visit for different reasons such as: contraindications, too high resting motor threshold or technical difficulties</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Repetitive TMS (rTMS)</title>
          <description>excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)&#xD;
repetitive transcranial magnetic stimulation: excitatory 5Hz rTMS will be used</description>
        </group>
        <group group_id="P2">
          <title>Sham Repetitive TMS (rTMS)</title>
          <description>electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)&#xD;
Sham repetitive transcranial magnetic stimulation: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>technical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who were randomized in the active or sham group.</population>
      <group_list>
        <group group_id="B1">
          <title>Repetitive TMS (rTMS)</title>
          <description>excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)&#xD;
repetitive transcranial magnetic stimulation: excitatory 5Hz rTMS will be used</description>
        </group>
        <group group_id="B2">
          <title>Sham Repetitive TMS (rTMS)</title>
          <description>electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)&#xD;
Sham repetitive transcranial magnetic stimulation: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Effect of a rTMS Session on Brain Activation as Measured by the Cerebral Blood Flow (Blood Oxygenation Level Dependent Signal)</title>
        <description>Blood oxygenation level dependent (BOLD) will be assessed to evaluate the acute effect of rTMS applied over the medial prefrontal cortex on the amygdala activation.&#xD;
This outcome (expressed a z-score) represents the amygdala activation, either after active rTMS or after sham rTMS.&#xD;
Higher z-scores for active than for sham rTMS indicates that amygdala activity increases after active rTMS compared to sham rTMS, on the other hand lower z-score after active rTMS vs. after Sham rTMS indicated that the amygdala activity would have been reduced with active rTMS.</description>
        <time_frame>right after the rTMS session, up to one hour</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Repetitive TMS (rTMS)</title>
            <description>excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)&#xD;
repetitive transcranial magnetic stimulation: excitatory 5Hz rTMS will be used</description>
          </group>
          <group group_id="O2">
            <title>Sham Repetitive TMS (rTMS)</title>
            <description>electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)&#xD;
Sham repetitive transcranial magnetic stimulation: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Effect of a rTMS Session on Brain Activation as Measured by the Cerebral Blood Flow (Blood Oxygenation Level Dependent Signal)</title>
          <description>Blood oxygenation level dependent (BOLD) will be assessed to evaluate the acute effect of rTMS applied over the medial prefrontal cortex on the amygdala activation.&#xD;
This outcome (expressed a z-score) represents the amygdala activation, either after active rTMS or after sham rTMS.&#xD;
Higher z-scores for active than for sham rTMS indicates that amygdala activity increases after active rTMS compared to sham rTMS, on the other hand lower z-score after active rTMS vs. after Sham rTMS indicated that the amygdala activity would have been reduced with active rTMS.</description>
          <population>Participants who completed the study</population>
          <units>z score in the amygdala</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.48"/>
                    <measurement group_id="O2" value="-0.48" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: Active rTMS applied over the node in the medial prefrontal cortex the most strongly negatively connected to the right amygdala will decrease amygdala BOLD activation compared to sham rTMS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.03</p_value>
            <p_value_desc>Give the limited sample size, this p-value was not adjusted for multiple comparisons. The threshold for statistical significant was p &lt; 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.15</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during rTMS application, and up to one hour after.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Repetitive TMS (rTMS)</title>
          <description>excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)&#xD;
repetitive transcranial magnetic stimulation: excitatory 5Hz rTMS will be used</description>
        </group>
        <group group_id="E2">
          <title>Sham Repetitive TMS (rTMS)</title>
          <description>electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)&#xD;
Sham repetitive transcranial magnetic stimulation: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Lysianne Beynel</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-1157</phone>
      <email>lysianne.beynel@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

